| Outcome Measures: |
Primary: Assessment of midazolam pharmacokinetic (PK) parameter: Area under the curve (AUC), Day 1 to Day 2 of Treatment A Period|Assessment of midazolam PK parameter: AUC, Day 11 to Day 12 of Treatment B Period|Assessment of metoprolol PK parameter: AUC, Day 1 to Day 3 of Treatment A Period|Assessment of metoprolol PK parameter: AUC, Day 11 to Day 13 of Treatment B Period | Secondary: Assessment of PK parameter: maximum plasma concentration (Cmax), Day 1 to Day 2 of Treatment A Period (midazolam)|Assessment of PK parameter: Cmax, Day 11 to Day 12 of Treatment B Period (midazolam)|Assessment of PK parameter: Cmax, Day 1 to Day 3 of Treatment A Period (metoprolol)|Assessment of PK parameter: Cmax, Day 11 to Day 13 of Treatment B Period (metoprolol)|Assessment of PK parameter: time to reach Cmax (Tmax), Day 1 to Day 2 of Treatment A Period (midazolam)|Assessment of PK parameter: Tmax, Day 11 to Day 12 of Treatment B Period (midazolam)|Assessment of PK parameter: Tmax, Day 1 to Day 3 of Treatment A Period (metoprolol)|Assessment of PK parameter: Tmax, Day 11 to Day 13 of Treatment B Period (metoprolol)|Assessment of PK parameter: terminal-half life (t1/2z), Day 1 to Day 2 of Treatment A Period (midazolam)|Assessment of PK parameter: t1/2z, Day 11 to Day 12 of Treatment B Period (midazolam)|Assessment of PK parameter: t1/2z, Day 1 to Day 3 of Treatment A Period (metoprolol)|Assessment of PK parameter: t1/2z, Day 11 to Day 13 of Treatment B Period (metoprolol)
|
